[ 1 ] Abbott KC, Agodoal LY. Multiple myeloma and light chain associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival[J]. Clin Nephrol, 2001, 56(3): 207 -210.
[2]
[ 2 ] Lamb EJ, Stowe HJ, Simpson DE, et al. Diagnostic accuracy of cystatin C as a marker of kidney disease in patients with multiple myeloma: calculated glomerular filtration rate formulas are equally useful[J]. Clin Chem, 2004, 50(10): 1848-1851.
[3]
[ 3 ] Heidtmann HH, Salge U, Abrahamson M, et al. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines[J]. Clin Exp Metastasis, 1997, 15(4): 368-381.
[4]
[ 4 ] Kos J, Stabuc B, Cimerman N, et al. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression[J]. Clin Chem, 1998, 44(11): 2256-2257.
[5]
[ 5 ] De Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays[J]. Oncogene, 2002, 21(44): 6848-6857.
[ 7 ] Herget-Rosenthal S, Marggraf G, Hüsing J, et al. Early detection of acute renal failure by serum cystatin C[J]. Kidney Int, 2004, 66(3): 1115-1122.
[8]
[ 8 ] Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: esults of a 4-year follow-up study[J]. J Am Soc Nephrol, 2005, 16(5):1404-1412.
[9]
[ 9 ] Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD[J]. Am J Kidney Dis, 2008, 51(3): 395-406.
[10]
Gertz MA, Lacy MQ, Dispenzieri A, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma[J]. Bone Marrow Transplant，2007, 39(10): 605-611.
[11]
Eleutherakis-Papaiakovou V, Bamia A, Gika D, et al. Renal failure in multiple myeloma: incidence correlations, and prognostic significance[J]. Leuk Lymphoma, 2007, 48(2): 337-341.
[12]
Brahamson M, Olafsson I, Palsdottir A, et al. Structure and expression of the human cystatin C gene[J]. Biochem J, 1990, 268（2）: 287-294.
[13]
Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma[J]. J Clin Oncol, 2005, 23(15): 3412-3420.
[14]
Finney H, Williams AH, Price CP. Serum cystatin C in patients with myeloma[J]. Clin Chim Acta, 2001, 309(1): 1-6.
[15]
Terpos E, Katodritou E, Tsiftsakis E, et al. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration[J]. Haematologica, 2009, 94(3): 372-379.
[16]
Choi SJ, Reddy SV, Devlin RD, et al. Identification of human asparaginyl endopeptidase (legumain) as an inhibitor of osteoclast formation and bone resorption[J]. J Biol Chem, 1999, 274(39): 27747-27753.
